It looks like your are using Internet Explorer.

Unfortunately, Internet Explorer is an outdated browser and we do not currently support it fully. You are seeing a limited view of the meeting details below.

To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 2)

30th November @ 10:45AM EDT

Unarguably, DTx solutions have clear benefits for patients. In the last few years, pharma companies have realised the potential of DTx to improve their offerings, especially companion DTx.  But the approach taken by pharma towards standalone DTx is a bit more cautious. What role does pharma have in standalone DTx? What are the needs and recommendations for pharma to launch successful standalone DTx? In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group.  

Some of the major challenges we may tackle (these are some examples - the group will agree on the problems they want to address):  


  • Immaturity of reimbursement models and figuring out a sustainable ROI model
  • Showing pharma the value of standalone DTx beyond new revenues
  • Traditional sales models that are inadequate for standalone DTx  
  • Finding the right talent and building specialised teams
  • Rigidity of internal traditional processes (e.g. regulatory, compliance, medical, legal, etc).

Please note: this is Part 2 of a two part session. Part 1 takes place on November 9th. Attendees must have taken part in the first session to participate in the second session.


We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.

Apply to Attend

Thank you! Your submission has been received.

An invite invite link has been sent to you if you do not already have a HealthXL account.
Oops! Something went wrong while submitting the form.

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 2)

Malin Johansson
Global Head of Digital Health Partnerships at Novo Nordisk
Karl Hess
Managing Director, Outcome Capital
Apply to Attend

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 2)

No items found.

Join this HealthXL Event today:

Participate in this Digital Health Sprint in order to:
- Deep dive into a topic over 2 focused sessions.
- Engage with a small group of 10 global thought-leaders throughout.
- This sprint is outcome-focused: HealthXL and participants create exclusive outputs.
- Grow your network with our break out sessions.


You actively participate in this discussion. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Don't miss your opportunity to connect with senior leaders to shape the future of digital health. Because only if you are prepared now can you lead the future.

30th November @ 10:45AM EDT

Unarguably, DTx solutions have clear benefits for patients. In the last few years, pharma companies have realised the potential of DTx to improve their offerings, especially companion DTx.  But the approach taken by pharma towards standalone DTx is a bit more cautious. What role does pharma have in standalone DTx? What are the needs and recommendations for pharma to launch successful standalone DTx? In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group.  

Some of the major challenges we may tackle (these are some examples - the group will agree on the problems they want to address):  


  • Immaturity of reimbursement models and figuring out a sustainable ROI model
  • Showing pharma the value of standalone DTx beyond new revenues
  • Traditional sales models that are inadequate for standalone DTx  
  • Finding the right talent and building specialised teams
  • Rigidity of internal traditional processes (e.g. regulatory, compliance, medical, legal, etc).

Please note: this is Part 2 of a two part session. Part 1 takes place on November 9th. Attendees must have taken part in the first session to participate in the second session.


We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.

Apply to AttendRegister to AttendApply to Attend

Participants

Participants

Malin Johansson

Global Head of Digital Health Partnerships at Novo Nordisk

Karl Hess

Managing Director, Outcome Capital

Louise O Mahony

Head of Healthcare Partnerships at EXi

Valentine Emmanuel

Experience Design & Strategy Lead, Daiichi Sankyo

Martin Svorc

Director Business Development Fertility, Merck Group

John Gordon

Digital Innovation Lab Lead - International Markets at Pfizer

Rafal Zasadny

Regulatory Affairs Manager at Bayer Consumer Care

Anthony Cam, Ph.D.

Global R&D Category Director, Digestive Health, Bayer

Jock Thompson

Chief Revenue Officer, Miku

Kevin Horgan

Chief Medical Officer, LOVE Inc

Vasyl Pyrozhyk

Associate, Sumitomo Mitsui Banking Corporation

Mark Slaughter

Senior Vice President, Sidekick Health

Number of Participants


Up to 12
Date  
November 30, 2022
Community

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 2)

Unarguably, DTx solutions have clear benefits for patients. In the last few years, pharma companies have realised the potential of DTx to improve their offerings, especially companion DTx.  But the approach taken by pharma towards standalone DTx is a bit more cautious. What role does pharma have in standalone DTx? What are the needs and recommendations for pharma to launch successful standalone DTx? In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group.  

Some of the major challenges we may tackle (these are some examples - the group will agree on the problems they want to address):  


  • Immaturity of reimbursement models and figuring out a sustainable ROI model
  • Showing pharma the value of standalone DTx beyond new revenues
  • Traditional sales models that are inadequate for standalone DTx  
  • Finding the right talent and building specialised teams
  • Rigidity of internal traditional processes (e.g. regulatory, compliance, medical, legal, etc).

Please note: this is Part 2 of a two part session. Part 1 takes place on November 9th. Attendees must have taken part in the first session to participate in the second session.


We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.

Participate in the Meeting

HealthXL Roundtables

HealthXL community meetings connect senior leaders from around the world.

Our virtual Roundtables are small, participant-led discussions where the HealthXL community discuss digital health challenges and offer solutions.

Participant-Led

HealthXL community members lead discussion on a defined topic among a maximum of 12 participants. There is no audience and no recordings, just an interactive space to reflect and share learnings.

Developed for a Busy Schedule

At 60-minutes long, roundtables are long enough for meaningful discussion among peers, but short enough to fit into busy schedules.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports

HealthXL Masterclasses

HealthXL community events give unparalleled access to digital health leaders from around the world.

Our virtual Masterclasses are 60-minute sessions where a recognised expert in their field provides an in-depth learning experience to a small audience of 8-12 members.

EXPERT-Led

HealthXL Masterclasses give you a chance to join a small group of peers and ask questions of recognised experts in a private, convenient setting.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports

HealthXL Webinars

HealthXL community events give unparalleled access to digital health experts from around the world.

Our webinars bring together panels of 3-4 global leaders from the HealthXL community to discuss core trends in digital health.

Expert Panel Discussion

Gain insights on the latest topics in digital health and ask questions of the expert panel via chat. Webinars run for 60 minutes and recordings are shared with all attendees afterwards.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports
Virtual Digital Health Meeting

Join from anywhere

No need for a high end laptop to display fancy 3D personas or interactive conference rooms: All you need is a working camera and an internet-ready device to join.

Apply to Attend now

The world of Digital Health in one Hub

Be ready for the future of Digital Health and join a community of passionate leaders, innovators and gamechangers. 

As a HealthXL member, you get access to a wealth of information, resources and connections. From daily curated news by our in-house expert team to industry reports each retailing at €2000 - you have the world of Digital Health right at your fingertips.

Our community is growing fast. Don’t miss out on your opportunity to lead the future.


Join the community here
Reports & Insights
Reports and insights shared by the DTx community
Curated
News
Daily DTx News Curated by our in-house experts
Lists & Dashboards
Interactive dashboards and downloadable organisation data

Your Digital Health Corner

All Posts
Events
April 2, 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: March 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: March 2024
Read More
Events
March 13, 2024
#ViVE2024 Unwrapped: Highlights and Insights
#ViVE2024 Unwrapped: Highlights and Insights
Read More
Commentary
February 16, 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: February 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: February 2024
Read More

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 2)

30th November @ 10:45AM EDT
Digital Therapeutics (DTx)

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 2)

30th November @ 10:45AM EDT
Digital Therapeutics (DTx)
Malin Johansson
Global Head of Digital Health Partnerships at Novo Nordisk
LinkedIn Profile
Karl Hess
Managing Director, Outcome Capital
LinkedIn Profile
Louise O Mahony
Head of Healthcare Partnerships at EXi
LinkedIn Profile
Valentine Emmanuel
Experience Design & Strategy Lead, Daiichi Sankyo
LinkedIn Profile
Martin Svorc
Director Business Development Fertility, Merck Group
LinkedIn Profile
John Gordon
Digital Innovation Lab Lead - International Markets at Pfizer
LinkedIn Profile
Rafal Zasadny
Regulatory Affairs Manager at Bayer Consumer Care
LinkedIn Profile
Anthony Cam, Ph.D.
Global R&D Category Director, Digestive Health, Bayer
LinkedIn Profile
Jock Thompson
Chief Revenue Officer, Miku
LinkedIn Profile
Kevin Horgan
Chief Medical Officer, LOVE Inc
LinkedIn Profile
Vasyl Pyrozhyk
Associate, Sumitomo Mitsui Banking Corporation
LinkedIn Profile
Mark Slaughter
Senior Vice President, Sidekick Health
LinkedIn Profile

Sprint: Conditions Needed for Pharma to Launch Standalone DTx (Part 2)

Unarguably, DTx solutions have clear benefits for patients. In the last few years, pharma companies have realised the potential of DTx to improve their offerings, especially companion DTx.  But the approach taken by pharma towards standalone DTx is a bit more cautious. What role does pharma have in standalone DTx? What are the needs and recommendations for pharma to launch successful standalone DTx? In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group.  

Some of the major challenges we may tackle (these are some examples - the group will agree on the problems they want to address):  


  • Immaturity of reimbursement models and figuring out a sustainable ROI model
  • Showing pharma the value of standalone DTx beyond new revenues
  • Traditional sales models that are inadequate for standalone DTx  
  • Finding the right talent and building specialised teams
  • Rigidity of internal traditional processes (e.g. regulatory, compliance, medical, legal, etc).

Please note: this is Part 2 of a two part session. Part 1 takes place on November 9th. Attendees must have taken part in the first session to participate in the second session.


We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.

When:
30th November @ 10:45AM EDT
Apply to attend
Registration Closed

Join this group of peers and get a feel of what it's like to belong to a community of digital health gamechangers.

All meetings are limited to 10 people to allow for honest discussions, so apply fast or become a HealthXL member and get priority access to all meetings, latest industry reports and and much more.

Frequently asked questions: 

What are HealthXL Virtual Meetings?

HealthXL Virtual Meetings are private group meetings limited to 10 people across different demographic and stakeholder groups. For 75 minutes, you take a deep dive into your chosen topic and explore it from different angles. Virtual Meetings are not webinars: There is no audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And through our Community Hub, you stay up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

How can I connect with other digital health leaders?

HealthXL brings together gamechangers of digital health to support honest discussions in small, private groups. In our Community Hub, for which you can register for free, you can follow a wide range of communities across telehealth, digital therapeutics, patient engagement and more. As a full HealthXL member, you also get access to curated news, the latest insights and an expert network to connect with. Join exclusive virtual meetings to exchange strategies, viewpoints and learnings with members from like-minded yet diverse stakeholder groups.

What are the benefits of being a HealthXL community member?

As member of HealthXL, you join a community of digital health thought leaders, innovators and game changers around the world. With your membership, you get access to hundreds of insights, reports and resources. You can browse a database with over 90k healthcare organizations and view their active strategic partnerships, commercial relationships, latest funding rounds and research. Through our in-house curated digital health newsfeed, you stay informed on the most impactful news and you can regularly meet with members to share learnings, discuss the latest developments and connect with peers of different demographical stakeholder groups. Contact us today to find out about pricing options.

Through focus groups, we bring together 6-10 thought leaders and industry stakeholders in a series of virtual meetings to collaborate around a defined topic. Each meeting gives the group the opportunity to examine, analyze and collaborate with one another around a digital health topic as well as produce a shareable result.